<DOC>
	<DOCNO>NCT00802347</DOCNO>
	<brief_summary>The purpose study determine whether single administration QPI-1002 ( also know I5NP ) prevent DGF patient undergo deceased donor kidney transplantation . In Phase I /II study , patient undergoing renal transplantation organ DCD donor , ECD donor SCD donor ≥ 24 hour cold ischemia time meet study entry criterion study evaluate safety pharmacokinetic profile I5NP ( Part A ) clinical activity I5NP administration ( Part B ) . Data study use identify dos I5NP use follow-on efficacy study . Part A randomized , dose escalation study determine high maximum tolerate dose ( MTD ) . Part A enroll 40 patient approximately 20 site ; patient randomize receive either I5NP placebo ratio 8:2 cohort ( cohorts 1-4 ) . Part B utilize dose identify Part A evaluate , double-blind manner , safety , clinical activity I5NP . In Part B , 326 patient participate approximately 60 site ; 163 patient randomized receive I5NP 163 patient randomized receive placebo .</brief_summary>
	<brief_title>I5NP Prophylaxis Delayed Graft Function Kidney Transplantation</brief_title>
	<detailed_description>Although etiology DGF fully understand may multifactorial , pathophysiology appear primarily relate ischemia-reperfusion ( IR ) injury result organ preservation time harvest donor reperfusion follow vascular reanastomosis recipient . I5NP small interfering RNA ( siRNA ) develop prophylaxis delay graft function ( DGF ) patient receive renal transplant .</detailed_description>
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>1 . Patient least 18 year age . 2 . Patient give informed consent . 3 . Patient willing practice birth control . Female patient must : ( 1 ) postmenopausal ( 2 ) surgically sterile , ( 3 ) use effective mean contraception ( per sitespecific guideline use 2 method birth control concurrently , whichever stringent ) continue Study Day 90 visit negative pregnancy test within 48 hour prior administration study drug . Male patient female partner child bear potential must agree use effective mean contraception ( per sitespecific guideline use 2 method birth control concurrently , whichever stringent ) continue Study Day 90 visit . Note : For purpose study , post menopausal define absence menses consistent ESRD . A woman consider surgically sterilize bilateral tubal ligation least 6 month prior administration study drug , bilateral oophorectomy , complete hysterectomy . 4 . Women childbearing potential test negative pregnancy ( either urine serum ) within 48 hour prior transplant . 5 . Patient uptodate cancer screen accord sitespecific guideline past medical history negative biopsyconfirmed malignancy within 5 year randomization , exception adequately treat basal cell squamous cell carcinoma situ . 6 . Patient schedule receive kidney transplant decease donor meeting follow criterion : Part A : receipt extend criterion donor ( ECD ) kidney , receipt kidney donate cardiac death ( DCD ) , receipt standard criterion donor ( SCD ) cold ischemia time ( CIT ) ≥ 24 hour . Part B : receipt ECD kidney preserve cold storage ( ECD/CS ) entire period cold ischemia time ( CIT ) , regardless duration receipt ECD kidney preserve machine perfusion ( ECD/MP ) interval time period cold ischemia , total CIT least 26 hour receipt SCD kidney preserve cold storage ( SCD/CS ) total CIT least 26 hour receipt SCD kidney preserve machine perfusion ( SCD/MP ) interval time period cold ischemia , total CIT least 26 hour . 7 . Patient dialysis dependent time transplant document : ) requirement least 2 dialysis sessions/week 56 day prior transplant , b ) plan removal remain native kidney time transplant , c ) opinion investigator patient remain native renal function ( Part A ) , ) investigator provide documentation Medical Monitor patient remain native renal function ( e.g. , documentation patient anuric , urine output &lt; 50 mL/day ) ( Part B ) . 1 . Patient participate investigational drug study last 30 day . 2 . Patient know allergy participate prior study siRNA . 3 . Patient HCVpositive 4 . Patient HIVpositive 5 . Patient schedule undergo multiorgan transplantation . 6 . Patient plan transplant kidney implant en bloc ( dual kidney transplant ) . 7 . Patient plan transplant kidney donor &lt; 6 year age . 8 . Patient plan transplant dual kidney ( donor ) transplant en bloc ( case dual ECD donor kidney ) . 9 . Patient schedule transplantation kidney donor know receive investigational therapy ( another IND ) ischemic/reperfusion injury immediately prior organ recovery . 10 . Patient schedule receive living donor kidney . 11 . Patient schedule receive ABOincompatible donor kidney . 12 . Patient schedule receive organ donor meet DCD ECD criterion . 13 . Patient schedule receive organ donor meet DCD criterion ( exclusion applicable Part B ) . 14 . Patient history presence medical condition disease investigator 's assessment would place patient unacceptable risk study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Delayed Graft Function</keyword>
	<keyword>Kidney Transplant</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>small interfere ribonucleic acid ( siRNA )</keyword>
</DOC>